Tech Company Financing Transactions

ImmusanT Funding Round

ImmusanT, based in Cambridge, secured $40 million in investment from Arch Venture Partners and Vatera Healthcare Partners.

Transaction Overview

Company Name
Announced On
11/15/2017
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Investors
Proceeds Purpose
The proceeds will fund a randomized Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene. Funds will also be used for the continued advancement of the company's diagnostic biomarker program and platform expansion.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 700
Cambridge, MA 02139
USA
Email Address
Overview
ImmusanT is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease.
Profile
ImmusanT LinkedIn Company Profile
Social Media
ImmusanT Company Twitter Account
Company News
ImmusanT News
Facebook
ImmusanT on Facebook
YouTube
ImmusanT on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Leslie Williams
  Leslie Williams LinkedIn Profile  Leslie Williams Twitter Account  Leslie Williams News  Leslie Williams on Facebook
Chief Medical Officer
Kenneth Truitt
  Kenneth Truitt LinkedIn Profile  Kenneth Truitt Twitter Account  Kenneth Truitt News  Kenneth Truitt on Facebook
Chief Scientific Officer
Robert Anderson
  Robert Anderson LinkedIn Profile  Robert Anderson Twitter Account  Robert Anderson News  Robert Anderson on Facebook
Vice President
Joyce Pinkham
  Joyce Pinkham LinkedIn Profile  Joyce Pinkham Twitter Account  Joyce Pinkham News  Joyce Pinkham on Facebook
VP - Bus. Development
Matan Dabora
  Matan Dabora LinkedIn Profile  Matan Dabora Twitter Account  Matan Dabora News  Matan Dabora on Facebook
VP - Finance
Jonathan Yeadon
  Jonathan Yeadon LinkedIn Profile  Jonathan Yeadon Twitter Account  Jonathan Yeadon News  Jonathan Yeadon on Facebook
VP - Operations
Kristin Neff
  Kristin Neff LinkedIn Profile  Kristin Neff Twitter Account  Kristin Neff News  Kristin Neff on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/15/2017: CleanCapital venture capital transaction
Next: 11/16/2017: GenomeDx Biosciences venture capital transaction

 

Share this article

 


News on VC Transactions

Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary